|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012634,
umls-concept:C0032743,
umls-concept:C0042295,
umls-concept:C0138741,
umls-concept:C0194810,
umls-concept:C0205251,
umls-concept:C0205329,
umls-concept:C0439275,
umls-concept:C1511790,
umls-concept:C1609982,
umls-concept:C1870012
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-5-31
|
|
pubmed:abstractText |
To assess the value of positron emission tomography (PET)/computed tomography (CT) with either (18)F-choline and/or (11)C-acetate, of residual or recurrent tumour after radical prostatectomy (RP) in patients with a prostate-specific antigen (PSA) level of <1 ng/mL and referred for adjuvant or salvage radiotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1464-4096
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1415-20
|
|
pubmed:meshHeading |
pubmed-meshheading:17428249-Acetates,
pubmed-meshheading:17428249-Aged,
pubmed-meshheading:17428249-Carbon Radioisotopes,
pubmed-meshheading:17428249-Choline,
pubmed-meshheading:17428249-Fluorine Radioisotopes,
pubmed-meshheading:17428249-Fluorodeoxyglucose F18,
pubmed-meshheading:17428249-Humans,
pubmed-meshheading:17428249-Magnetic Resonance Imaging,
pubmed-meshheading:17428249-Male,
pubmed-meshheading:17428249-Middle Aged,
pubmed-meshheading:17428249-Neoplasm, Residual,
pubmed-meshheading:17428249-Neoplasm Recurrence, Local,
pubmed-meshheading:17428249-Positron-Emission Tomography,
pubmed-meshheading:17428249-Prostate-Specific Antigen,
pubmed-meshheading:17428249-Prostatectomy,
pubmed-meshheading:17428249-Prostatic Neoplasms,
pubmed-meshheading:17428249-Radiopharmaceuticals,
pubmed-meshheading:17428249-Salvage Therapy,
pubmed-meshheading:17428249-Tomography, X-Ray Computed,
pubmed-meshheading:17428249-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
|
|
pubmed:affiliation |
Service of Radiation Oncology, University Hospital, Geneva, Switzerland. Hansjorg.Vees@hcuge.ch
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Evaluation Studies
|
